Personalised treatment of arthritis in the next eRA

Netherlands Journal of Medicine

Volumn 67, Issue 11, 2009, Pages 362-363

  Tas, S W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; METHOTREXATE; RITUXIMAB; TOCILIZUMAB;

CYTOKINE PRODUCTION; DRUG COST; DRUG MECHANISM; EDITORIAL; GENETIC HETEROGENEITY; HUMAN; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PHARMACOGENETICS; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74849097786     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5(10):531-41.
2. Tak PP. Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment? J Rheumatol Suppl. 2005;72:25-6.
3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis. 2009;68(8):1368-9.
4. Thurlings RM, Wijbrandts CA, Mebius RE, et al. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum. 2008;58(6):1582-9.
5. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci. 2003;987:140-9.
6. Timmer TC, Baltus B, Vondenhoff M, et al. Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum. 2007;56(8):2492-502.
7. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66(8):1008-14.
8. Van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003;48(8):2132-45.
9. Hamilton JA, Tak PP. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 2009;60(5):1210-21.
10. Gerlag DM, Boyle DL, Rosengren S, Nash T, Tak PP, Firestein GS. Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment. Ann Rheum Dis. 2007;66(4):545-7.
11. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis. 2008;67(8):1139-44.
12. Van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Ann Rheum Dis. 2008;67(4):563-6.
13. Gerlag DM, Tak PP. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol. 2008;22(2):311-23.
14. Verweij CL. Transcript profiling towards personalized medicine in rheumatoid arthritis. Neth J Med. 2009;67(11):364-71.
15. Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008;58(5):1284-92.
16. Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58(4):1001-9.